Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conbercept for Macular Edema in CRVO (CRAVE)
NCT03223714Phase 3Completed
- Sponsor
- Chengdu Kanghong Pharmaceutical Group Co., Ltd.
- Start
- May 2016
- Primary completion
- Apr 2020
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of conbercept in macular edema secondary to central retinal vein occlusion (ME-CRVO), sponsored by Chengdu Kanghong Pharmaceutical Group Co., Ltd. Primary endpoint: Best Corrected Visual Acuity at 6 months. Started May 2016; status: completed.
02
Drugs
conbercept
03
Conditions
macular edema secondary to central retinal vein occlusion (ME-CRVO)
Beyond the preview
Go deeper on NCT03223714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03223714.